nodes	percent_of_prediction	percent_of_DWPC	metapath
Gatifloxacin—Rash—Mechlorethamine—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Gatifloxacin—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Gatifloxacin—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Gatifloxacin—Anorexia—Fludarabine—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Gatifloxacin—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Gatifloxacin—Feeling abnormal—Teniposide—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Gatifloxacin—Stomatitis—Vincristine—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Gatifloxacin—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Gatifloxacin—Chills—Bleomycin—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Gatifloxacin—Sweating—Vincristine—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Gatifloxacin—Nausea—Mechlorethamine—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Gatifloxacin—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Gatifloxacin—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Gatifloxacin—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Gatifloxacin—Urticaria—Teniposide—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Gatifloxacin—Glossitis—Methotrexate—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Gatifloxacin—Abdominal pain—Teniposide—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Gatifloxacin—Body temperature increased—Teniposide—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Gatifloxacin—Erythema—Bleomycin—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Gatifloxacin—Paraesthesia—Fludarabine—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Gatifloxacin—Hallucination—Carmustine—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Gatifloxacin—Sweating—Mitoxantrone—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Gatifloxacin—Dyspnoea—Fludarabine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Gatifloxacin—Haematuria—Mitoxantrone—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Gatifloxacin—Oedema peripheral—Carmustine—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Gatifloxacin—Dyspepsia—Fludarabine—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Gatifloxacin—Decreased appetite—Fludarabine—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Gatifloxacin—Visual impairment—Carmustine—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Gatifloxacin—Hallucination—Vincristine—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Gatifloxacin—Constipation—Fludarabine—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Gatifloxacin—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Gatifloxacin—Eye disorder—Carmustine—lymphatic system cancer	0.00294	0.00294	CcSEcCtD
Gatifloxacin—Hypersensitivity—Teniposide—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Gatifloxacin—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Gatifloxacin—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Gatifloxacin—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Gatifloxacin—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Gatifloxacin—Asthenia—Teniposide—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Gatifloxacin—Pruritus—Teniposide—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Gatifloxacin—Body temperature increased—Fludarabine—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Gatifloxacin—Vaginal infection—Methotrexate—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Gatifloxacin—Erythema—Carmustine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Gatifloxacin—Diarrhoea—Teniposide—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Gatifloxacin—Chest pain—Bleomycin—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Gatifloxacin—Myalgia—Bleomycin—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Gatifloxacin—Back pain—Carmustine—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Gatifloxacin—Chills—Mitoxantrone—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Gatifloxacin—Mouth ulceration—Methotrexate—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Gatifloxacin—Ecchymosis—Methotrexate—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Gatifloxacin—Confusional state—Bleomycin—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Gatifloxacin—Vision blurred—Carmustine—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Gatifloxacin—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Gatifloxacin—Tremor—Carmustine—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Gatifloxacin—Oedema—Bleomycin—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Gatifloxacin—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Gatifloxacin—Erythema—Mitoxantrone—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Gatifloxacin—Infection—Bleomycin—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Gatifloxacin—Back pain—Vincristine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Gatifloxacin—Vomiting—Teniposide—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Gatifloxacin—Agitation—Carmustine—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Gatifloxacin—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Gatifloxacin—Asthenia—Fludarabine—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Gatifloxacin—Rash—Teniposide—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Gatifloxacin—Dermatitis—Teniposide—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Gatifloxacin—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Gatifloxacin—Headache—Teniposide—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Gatifloxacin—Pruritus—Fludarabine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Gatifloxacin—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Gatifloxacin—Back pain—Mitoxantrone—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Gatifloxacin—Anorexia—Bleomycin—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Gatifloxacin—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Gatifloxacin—Agitation—Vincristine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Gatifloxacin—Vision blurred—Mitoxantrone—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Gatifloxacin—Photosensitivity—Methotrexate—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Gatifloxacin—Hypotension—Bleomycin—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Gatifloxacin—Diarrhoea—Fludarabine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Gatifloxacin—Convulsion—Carmustine—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Gatifloxacin—Hypertension—Carmustine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Gatifloxacin—Nausea—Teniposide—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Gatifloxacin—Vertigo—Vincristine—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Gatifloxacin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Gatifloxacin—Myalgia—Carmustine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Gatifloxacin—Chest pain—Carmustine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Gatifloxacin—Anxiety—Carmustine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Gatifloxacin—Paraesthesia—Bleomycin—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Gatifloxacin—Dyspnoea—Bleomycin—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Gatifloxacin—Renal failure acute—Methotrexate—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Gatifloxacin—Convulsion—Vincristine—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Gatifloxacin—Hypertension—Vincristine—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Gatifloxacin—Confusional state—Carmustine—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Gatifloxacin—Oedema—Carmustine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Gatifloxacin—Decreased appetite—Bleomycin—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Gatifloxacin—Myalgia—Vincristine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Gatifloxacin—Infection—Carmustine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Gatifloxacin—Vomiting—Fludarabine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Gatifloxacin—Convulsion—Mitoxantrone—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Gatifloxacin—Rash—Fludarabine—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Gatifloxacin—Dermatitis—Fludarabine—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Gatifloxacin—Hypertension—Mitoxantrone—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Gatifloxacin—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Gatifloxacin—Headache—Fludarabine—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Gatifloxacin—Tachycardia—Carmustine—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Gatifloxacin—Chest pain—Mitoxantrone—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Gatifloxacin—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Gatifloxacin—Myalgia—Mitoxantrone—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Gatifloxacin—Anxiety—Mitoxantrone—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Gatifloxacin—Oedema—Vincristine—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Gatifloxacin—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Gatifloxacin—Anorexia—Carmustine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Gatifloxacin—Infection—Vincristine—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Gatifloxacin—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Gatifloxacin—Confusional state—Mitoxantrone—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Gatifloxacin—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Gatifloxacin—Hypotension—Carmustine—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Gatifloxacin—Oedema—Mitoxantrone—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Gatifloxacin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Gatifloxacin—Nausea—Fludarabine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Gatifloxacin—Infection—Mitoxantrone—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Gatifloxacin—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Gatifloxacin—Shock—Mitoxantrone—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Gatifloxacin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Gatifloxacin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Gatifloxacin—Urticaria—Bleomycin—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Gatifloxacin—Anorexia—Vincristine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Gatifloxacin—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Gatifloxacin—Body temperature increased—Bleomycin—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Gatifloxacin—Insomnia—Carmustine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Gatifloxacin—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Gatifloxacin—Paraesthesia—Carmustine—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Gatifloxacin—Hypotension—Vincristine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Gatifloxacin—Dyspnoea—Carmustine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Gatifloxacin—Somnolence—Carmustine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Gatifloxacin—Anorexia—Mitoxantrone—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Gatifloxacin—Ataxia—Methotrexate—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Gatifloxacin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Gatifloxacin—Decreased appetite—Carmustine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Gatifloxacin—Hypotension—Mitoxantrone—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Gatifloxacin—Insomnia—Vincristine—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Gatifloxacin—Paraesthesia—Vincristine—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Gatifloxacin—Constipation—Carmustine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Gatifloxacin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Gatifloxacin—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Gatifloxacin—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Gatifloxacin—Decreased appetite—Vincristine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Gatifloxacin—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Gatifloxacin—Somnolence—Mitoxantrone—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Gatifloxacin—Feeling abnormal—Carmustine—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Gatifloxacin—Asthenia—Bleomycin—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Gatifloxacin—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Gatifloxacin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Gatifloxacin—Constipation—Vincristine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Gatifloxacin—Asthma—Methotrexate—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Gatifloxacin—Pruritus—Bleomycin—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Gatifloxacin—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Gatifloxacin—Pancreatitis—Methotrexate—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Gatifloxacin—Constipation—Mitoxantrone—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Gatifloxacin—Abdominal pain—Carmustine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Gatifloxacin—Body temperature increased—Carmustine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Gatifloxacin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Gatifloxacin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Gatifloxacin—Dysuria—Methotrexate—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Gatifloxacin—Neutropenia—Methotrexate—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Gatifloxacin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Gatifloxacin—Body temperature increased—Vincristine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Gatifloxacin—Abdominal pain—Vincristine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Gatifloxacin—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Gatifloxacin—Urticaria—Mitoxantrone—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Gatifloxacin—Hypersensitivity—Carmustine—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Gatifloxacin—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Gatifloxacin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Gatifloxacin—Vomiting—Bleomycin—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Gatifloxacin—Rash—Bleomycin—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Gatifloxacin—Dermatitis—Bleomycin—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Gatifloxacin—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Gatifloxacin—Asthenia—Carmustine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Gatifloxacin—Stomatitis—Methotrexate—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Gatifloxacin—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Gatifloxacin—Hypersensitivity—Vincristine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Gatifloxacin—Sweating—Methotrexate—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Gatifloxacin—Haematuria—Methotrexate—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Gatifloxacin—Epistaxis—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Gatifloxacin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Gatifloxacin—Asthenia—Vincristine—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Gatifloxacin—Diarrhoea—Carmustine—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Gatifloxacin—Nausea—Bleomycin—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Gatifloxacin—Asthenia—Mitoxantrone—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Gatifloxacin—Dizziness—Carmustine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Gatifloxacin—Diarrhoea—Vincristine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Gatifloxacin—Hepatitis—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Gatifloxacin—Pharyngitis—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Gatifloxacin—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Gatifloxacin—Vomiting—Carmustine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Gatifloxacin—Dizziness—Vincristine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Gatifloxacin—Rash—Carmustine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Gatifloxacin—Dermatitis—Carmustine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Gatifloxacin—Visual impairment—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Gatifloxacin—Headache—Carmustine—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Gatifloxacin—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Gatifloxacin—Eye disorder—Methotrexate—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Gatifloxacin—Tinnitus—Methotrexate—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Gatifloxacin—Vomiting—Vincristine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Gatifloxacin—Rash—Vincristine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Gatifloxacin—Dermatitis—Vincristine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Gatifloxacin—Headache—Vincristine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Gatifloxacin—Nausea—Carmustine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Gatifloxacin—Vomiting—Mitoxantrone—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Gatifloxacin—Rash—Mitoxantrone—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Gatifloxacin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Gatifloxacin—Chills—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Gatifloxacin—Headache—Mitoxantrone—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Gatifloxacin—Erythema—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Gatifloxacin—Nausea—Vincristine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Gatifloxacin—Dysgeusia—Methotrexate—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Gatifloxacin—Nausea—Mitoxantrone—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Gatifloxacin—Back pain—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Gatifloxacin—Vision blurred—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Gatifloxacin—Vertigo—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Gatifloxacin—Convulsion—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Gatifloxacin—Myalgia—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Gatifloxacin—Arthralgia—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Gatifloxacin—Chest pain—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Gatifloxacin—Confusional state—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Gatifloxacin—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Gatifloxacin—Infection—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Gatifloxacin—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Gatifloxacin—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.001	0.001	CcSEcCtD
Gatifloxacin—Anorexia—Methotrexate—lymphatic system cancer	0.000988	0.000988	CcSEcCtD
Gatifloxacin—Hypotension—Methotrexate—lymphatic system cancer	0.000968	0.000968	CcSEcCtD
Gatifloxacin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000944	0.000944	CcSEcCtD
Gatifloxacin—Insomnia—Methotrexate—lymphatic system cancer	0.000937	0.000937	CcSEcCtD
Gatifloxacin—Paraesthesia—Methotrexate—lymphatic system cancer	0.000931	0.000931	CcSEcCtD
Gatifloxacin—Dyspnoea—Methotrexate—lymphatic system cancer	0.000924	0.000924	CcSEcCtD
Gatifloxacin—Somnolence—Methotrexate—lymphatic system cancer	0.000921	0.000921	CcSEcCtD
Gatifloxacin—Dyspepsia—Methotrexate—lymphatic system cancer	0.000912	0.000912	CcSEcCtD
Gatifloxacin—Decreased appetite—Methotrexate—lymphatic system cancer	0.000901	0.000901	CcSEcCtD
Gatifloxacin—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000854	0.000854	CcSEcCtD
Gatifloxacin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000848	0.000848	CcSEcCtD
Gatifloxacin—Urticaria—Methotrexate—lymphatic system cancer	0.000823	0.000823	CcSEcCtD
Gatifloxacin—Abdominal pain—Methotrexate—lymphatic system cancer	0.000819	0.000819	CcSEcCtD
Gatifloxacin—Body temperature increased—Methotrexate—lymphatic system cancer	0.000819	0.000819	CcSEcCtD
Gatifloxacin—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000764	0.000764	CcSEcCtD
Gatifloxacin—Asthenia—Methotrexate—lymphatic system cancer	0.000744	0.000744	CcSEcCtD
Gatifloxacin—Pruritus—Methotrexate—lymphatic system cancer	0.000733	0.000733	CcSEcCtD
Gatifloxacin—Diarrhoea—Methotrexate—lymphatic system cancer	0.000709	0.000709	CcSEcCtD
Gatifloxacin—Dizziness—Methotrexate—lymphatic system cancer	0.000685	0.000685	CcSEcCtD
Gatifloxacin—Vomiting—Methotrexate—lymphatic system cancer	0.000659	0.000659	CcSEcCtD
Gatifloxacin—Rash—Methotrexate—lymphatic system cancer	0.000654	0.000654	CcSEcCtD
Gatifloxacin—Dermatitis—Methotrexate—lymphatic system cancer	0.000653	0.000653	CcSEcCtD
Gatifloxacin—Headache—Methotrexate—lymphatic system cancer	0.000649	0.000649	CcSEcCtD
Gatifloxacin—Nausea—Methotrexate—lymphatic system cancer	0.000616	0.000616	CcSEcCtD
